MSMO1 (methylsterol monooxygenase 1) catalyzes C4 demethylation of sterol intermediates, a critical step in distal cholesterol biosynthesis that converts 4,4-dimethyl and 4α-methylsterols to cholesterol 1. The enzyme also metabolizes vitamin D analogs, converting eldecalcitol to 1α,2β,25-trihydroxy vitamin D3 through enzymatic hydroxylation [referenced in UniProt data]. MSMO1 functions as a ferroptosis suppressor by maintaining 7-dehydrocholesterol levels, which shields cellular membranes from phospholipid autoxidation 2. Loss of MSMO1 function causes developmental delay, microcephaly, congenital cataracts, and psoriasiform dermatitis; these manifestations result from both cholesterol deprivation and sterol intermediate accumulation 13. MSMO1 deficiency is an ultrarare autosomal recessive disorder with only limited reported cases, though oral cholesterol supplementation combined with statins shows promise in ameliorating cutaneous and immunological manifestations 1. Beyond monogenic disease, MSMO1 appears dysregulated in complex diseases: elevated expression correlates with poor outcomes in sepsis through lipid dysregulation 4, reduced expression associates with Parkinson's disease pathology 5, and MSMO1 modulates osteosarcoma progression through glutamine metabolism pathways 6. MSMO1's broader role in disease suggests its integration into metabolic signaling networks beyond simple cholesterol synthesis.